Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

The Lancet

Volumn 388, Issue 10056, 2016, Pages 2128-2141

  FitzGerald, J Mark ^a   Bleecker, Eugene R ^b   Nair, Parameswaran ^c   Korn, Stephanie ^d   Ohta, Ken ^e   Lommatzsch, Marek ^f   Ferguson, Gary T ^g   Busse, William W ^h   Barker, Peter ⁱ   Sproule, Stephanie ⁱ   Gilmartin, Geoffrey ⁱ   Werkström, Viktoria ^j   Aurivillius, Magnus ^j   Goldman, Mitchell ⁱ  

^a VANCOUVER GENERAL HOSPITAL   (Canada)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e TOKYO NATIONAL HOSPITAL   (Japan)

^f ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^g Pulmonary Research Institute of Southeast Michigan   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ ASTRAZENECA   (United Kingdom)

^j ASTRAZENECA R AND D   (Sweden)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENRALIZUMAB; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; PLACEBO; ANTIASTHMATIC AGENT; INTERLEUKIN 5 RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE SINUSITIS; ADD ON THERAPY; ADOLESCENT; ADULT; AGED; ALLERGIC RHINITIS; ARTHRALGIA; ARTICLE; ASTHMA; BACKACHE; BRONCHITIS; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; COUGHING; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EMERGENCY WARD; EOSINOPHIL COUNT; FEMALE; FEVER; FOLLOW UP; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; HYPERSENSITIVITY; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SINUSITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; DISEASE COURSE; DOSE RESPONSE; INHALATIONAL DRUG ADMINISTRATION; LOEFFLER PNEUMONIA; MIDDLE AGED; MULTICENTER STUDY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CHILD; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PULMONARY EOSINOPHILIA; RECEPTORS, INTERLEUKIN-5;

EID: 84994910846     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)31322-8     Document Type: Article

References (30)

1. 1 To, T, Stanojevic, S, Moores, G, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health, 12, 2012, 204.
2. 2 Chung, KF, Wenzel, SE, Brozek, JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 43 (2014), 343–373.
3. 3 Peters, SP, Ferguson, G, Deniz, Y, Reisner, C, Uncontrolled asthma: a review of the prevalence, disease burden and options for treatment. Respir Med 100 (2006), 1139–1151.
4. 4 Pavord, ID, Haldar, P, Bradding, P, Wardlaw, AJ, Mepolizumab in refractory eosinophilic asthma. Thorax, 65, 2010, 370.
5. 5 Parameswaran, K, Lemiere, C, Kamada, D, O'Byrne, PM, Hargreave, FE, Predictors of loss of asthma control induced by corticosteroid withdrawal. Can Respir J 13 (2006), 129–133.
6. 6 Louis, R, Lau, LC, Bron, AO, Roldaan, AC, Radermecker, M, Djukanovic, R, The relationship between airways inflammation and asthma severity. Am J Respir Crit Care Med 161 (2000), 9–16.
7. 1 decline in occupational asthma: results of an observational study. BMJ Open, 5, 2015, e005748.
8. 8 Green, RH, Brightling, CE, McKenna, S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360 (2002), 1715–1721.
9. 9 Tan, LD, Bratt, JM, Godor, D, Louie, S, Kenyon, NJ, Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy 9 (2016), 71–81.
10. 10 Global Initiative for Asthma. Global strategy for asthma management and prevention. http://www.ginasthma.org, 2016 (accessed May 5, 2016).
11. 11 Teva Respiratory, LLC, Cinqair (reslizumab) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761033lbl.pdf, 2016 (accessed June 12, 2016).
12. 12 GlaxoSmithKline, LLC, Nucala (mepolizumab) prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125526Orig1s000Lbl.pdf, 2015 (accessed June 12, 2016).
13. 13 Castro, M, Zangrilli, J, Wechsler, ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3 (2015), 355–366.
14. 14 Ortega, HG, Liu, MC, Pavord, ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 (2014), 1198–1207.
15. 15 Ortega, HG, Yancey, SW, Mayer, B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med 4 (2016), 549–556.
16. 16 Pavord, ID, Korn, S, Howarth, P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380 (2012), 651–659.
17. 17 Castro, M, Mathur, S, Hargreave, F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 184 (2011), 1125–1132.
18. 18 Kolbeck, R, Kozhich, A, Koike, M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125 (2010), 1344–1353 e2.
19. 19 Flood-Page, P, Swenson, C, Faiferman, I, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 (2007), 1062–1071.
20. 20 Ghazi, A, Trikha, A, Calhoun, WJ, Benralizumab—a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity – a novel approach for the treatment of asthma. Expert Opin Biol Ther 12 (2012), 113–118.
21. 21 Busse, WW, Katial, R, Gossage, D, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 125 (2010), 1237–1244.
22. 22 Laviolette, M, Gossage, DL, Gauvreau, G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 132 (2013), 1086–1096.
23. 23 Castro, M, Wenzel, SE, Bleecker, ER, et al. Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. Lancet Respir Med 2 (2014), 879–890.
24. 24 Juniper, EF, O'Byrne, PM, Ferrie, PJ, King, DR, Roberts, JN, Measuring asthma control. Clinic questionnaire or daily diary?. Am J Respir Crit Care Med 162 (2000), 1330–1334.
25. 25 Juniper, EF, Svensson, K, Mork, AC, Stahl, E, Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 99 (2005), 553–558.
26. 26 Juniper, EF, Svensson, K, Mork, AC, Stahl, E, Modification of the asthma quality of life questionnaire (standardised) for patients 12 years and older. Health Qual Life Outcomes, 3, 2005, 58.
27. 27 Wang, B, Yan, L, Hutmacher, M, et al. Exposure-response analysis for determination of benralizumab optimal dosing regimens in adults with asthma. Am J Respir Crit Care Med, 189, 2014, A1324.
28. 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet, 2016 published online Sept 5. http://dx.doi.org/10.1016/S0140-6736(16)31324-1.
29. 29 Rudulier, CD, Larche, M, Moldaver, D, Treatment with anti-cytokine monoclonal antibodies can potentiate the target cytokine rather than neutralize its activity. Allergy 71 (2016), 283–285.
30. 2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet 388 (2016), 31–44.